# Nutrition rehabilitation programs and cachexia clinics for anorexia–cachexia syndrome in patients with cancer

**Authors:** Rony Dev, Kunal C Kadakia, Jegy M Tennison, Koji Amano, Michele Szafranski, Eduardo Bruera, Tateaki Naito, Egidio Del Fabbro

PMC · DOI: 10.1093/oncolo/oyag042 · The Oncologist · 2026-02-16

## TL;DR

This paper discusses how specialized clinics and rehabilitation programs can help manage weight loss and poor nutrition in cancer patients with anorexia–cachexia syndrome.

## Contribution

The paper emphasizes the need for interdisciplinary clinics to address the complex nature of anorexia–cachexia syndrome in cancer patients.

## Key findings

- ACS is driven by complex metabolic and inflammatory mechanisms that cannot be reversed by standard nutrition alone.
- Interdisciplinary teams are essential to manage nutrition impact symptoms and improve outcomes in ACS patients.
- Specialized clinics can help integrate new treatments into the management of anorexia–cachexia syndrome.

## Abstract

The anorexia–cachexia syndrome (ACS) is characterized by loss of appetite and unintentional weight loss. Important clinical outcomes are associated with ACS including increased risk of chemotherapy side effects, decreased survival, and quality of life. Because ACS is driven by complex metabolic mechanisms and a chronic pro-inflammatory response, the weight loss and muscle wasting cannot be reversed by conventional nutritional supplementation alone. However, insufficient intake of calories and protein exacerbate weight loss experienced by patients with ACS, while physical inactivity accelerate muscle wasting. In addition, uncontrolled symptoms, such as pain, mucositis, nausea, early satiety, and depression aggravate poor nutritional intake and are known as nutrition impact symptoms. Addressing these potentially reversible contributors to ACS requires an interdisciplinary team (IDT) effort including oncologists, palliative medicine, rehabilitation clinicians, dietitians, and psychologists. The composition and leadership of the team depends on institutional support and the patient population being treated (eg, advanced cancer vs peri-operative rehabilitation vs geriatric). Because patients may be burdened by frequent visits to multiple healthcare providers and a special skill set is required of the IDT to address ACS—measuring caloric and protein intake, assessing body composition, optimal symptom management, and providing psycho-social support–a specialized clinic would be ideal. As more effective anti-cachexia agents are being developed, nutritional rehabilitation programs and cachexia clinics could facilitate incorporation of novel treatments into multimodal management of ACS. The narrative review highlights the management of nutrition impact symptoms and the potential benefits and challenges of specialized nutrition rehabilitation programs and cachexia clinics.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC5A5 (solute carrier family 5 member 5) [NCBI Gene 6528] {aka NIS, TDH1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** mood disorders (MESH:D019964), dry mouth (MESH:D014987), weight gain (MESH:D015430), nausea and vomiting (MESH:D020250), Depression (MESH:D003866), sarcopenic obesity (MESH:D009765), mucositis (MESH:D052016), excess adiposity (MESH:D018205), falls (MESH:C537863), neuropathic pain (MESH:D009437), nausea (MESH:D009325), Fatigue (MESH:D005221), gastroparesis (MESH:D018589), ACS (MESH:D002100), B12 deficiency (MESH:D014806), wasting (MESH:D019282), appetite loss (MESH:D001068), Constipation (MESH:D003248), diarrhea (MESH:D003967), hypogonadism (MESH:D007006), esophageal cancer (MESH:D004938), hematological malignancies (MESH:D019337), eating-related distress (MESH:D012128), non-small cell lung cancer (MESH:D002289), Decreased muscle mass (MESH:C536030), functional impairment (MESH:D003072), taste and smell disturbances (MESH:D000857), HGS (MESH:D006230), vomiting (MESH:D014839), solid (MESH:D018250), nutrition impact symptoms (MESH:D009748), sarcopenia (MESH:D055948), activity (OMIM:612348), Inflammation (MESH:D007249), Muscle wasting (MESH:D009133), ESC (MESH:D003428), difficulty swallowing (MESH:D003680), Symptom (MESH:D012816), abnormal taste (MESH:D013651), death (MESH:D003643), hypothyroidism (MESH:D007037), Malnutrition (MESH:D044342), pain (MESH:D010146), altered (MESH:D004408), leukemia (MESH:D007938), Colorectal Cancer (MESH:D015179), lung cancer (MESH:D008175), shortness of breath (MESH:D004417), psychiatric (MESH:D001523), Adrenal insufficiency (MESH:D000309), CNRP (MESH:D009369), loss of function (MESH:D006315), weakness (MESH:D018908), weight loss (MESH:D015431), head and neck cancer (MESH:D006258), Anxiety (MESH:D001007), Anorexia (MESH:D000855)
- **Chemicals:** testosterone (MESH:D013739), metoclopramide (MESH:D008787), ondansetron (MESH:D017294), CINV (-), ibuprofen (MESH:D007052), megestrol acetate (MESH:D019290), zinc (MESH:D015032), olanzapine (MESH:D000077152), omega-3-fatty acid (MESH:D015525), duloxetine (MESH:D000068736), mirtazapine (MESH:D000078785)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958113/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12958113/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958113/full.md

---
Source: https://tomesphere.com/paper/PMC12958113